Table 2 Sensitivity and specificity in the training set and test set
Patient group | Training set | Test set | ||||||
|---|---|---|---|---|---|---|---|---|
Tested | Positive | Sensitivity (%) | Specificity (%) | Tested | Positive | Sensitivity (%) | Specificity (%) | |
Early stage | 23 | 19 | 82.6% (61.2–95.0%) |  | 26 | 17 | 65.4% (44.3–82.8%) |  |
Late stage | 20 | 18 | 90.0% (68.3–98.8%) |  | 16 | 15 | 93.8% (69.8–99.8%) |  |
All cancer | 43 | 37 | 86.0% (72.2–94.8%) |  | 42 | 32 | 76.2% (60.5–87.9%) |  |
Benign | 5 | 1 | 20.0% (0.5–71.4%) | 80.0% (28.4–99.5%) | 5 | 1 | 20.0% (0.5–71.4%) | 80.0% (28.4–99.5%) |
Healthy control | 62 | 3 |  | 95.2% (86.5–99.0%) | 63 | 3 |  | 95.2% (86.7–99.0%) |
All non-cancer | 67 | 4 |  | 94.0% (85.5–98.3%) | 68 | 4 |  | 94.1% (85.7–98.4%) |